Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥70 years with ultralow risk of distant recurrence: A population-based cohort study

Mansani, Fábio Postiglione; Freitas‐Júnior, Ruffo

doi:10.1016/j.jgo.2023.101526

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, with the growing complexity of treatment scenario, in which both escalation and de-escalation strategies are available, the identification of additional biomarkers to properly stratify patients’ risk and sensitivity to ET represents a significant clinical need. In this regard, genomic assays represent an attractive biomarker as they have already proven to be a valuable tool to guide adjuvant chemotherapy decision in early-stage HR+/HER2− breast cancers ( 53 , 54 ) and have been evaluated with a similar aim in the neoadjuvant setting ( 55 ).…”

Section: Discussionmentioning

confidence: 99%

Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer

Bottosso,

Miglietta,

Vernaci

et al. 2024

Clinical Cancer Research

View full text Add to dashboard Cite

Adjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond currently used clinicopathological characteristics. Several gene-expression assays have been developed to identify patients with HR+/HER2- breast cancer who will not derive benefit from the addition of adjuvant chemotherapy. By enhancing risk stratification and predicting therapeutic response, genomic assays have also shown to be a promising tool for optimizing endocrine treatment decision. We here review evidence supporting the use of most common commercially available gene-expression assays (Oncotype DX, MammaPrint, Breast Cancer Index, Prosigna and EndoPredict) in tailoring adjuvant endocrine therapy. Available data on the use of genomic tests to inform extended adjuvant treatment choice based on the risk of late relapse and on the estimated benefit of a prolonged endocrine therapy are discussed. Moreover, preliminary evidence regarding the use of genomic assays to inform de-escalation of endocrine treatment, such as shorter durations or omission, for low risk patients are reviewed. Overall, gene expression assays are emerging as potential tools to further personalize adjuvant treatment for patients with HR+/HER2- breast cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer

Bottosso,

Miglietta,

Vernaci

et al. 2024

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…The robust performance of MammaPrint has been substantiated through multiple studies, firmly establishing its prognostic and predictive capabilities. Notably, it excels at identifying patients with a low risk of recurrence, offering them the potential benefit of avoiding unnecessary chemotherapy [ 39 , 40 ]. The prognostic validity of MammaPrint received noteworthy validation through the RASTER study, marking the first prospective examination of its performance in patients with cT1-3N0M0 BC.…”

Section: Clinical Validity and Clinical Utilitymentioning

confidence: 99%

The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy

Venetis,

Pescia,

Cursano

et al. 2024

IJMS

View full text Add to dashboard Cite

Multigene prognostic genomic assays have become indispensable in managing early breast cancer (EBC), offering crucial information for risk stratification and guiding adjuvant treatment strategies in conjunction with traditional clinicopathological parameters. The American Society of Clinical Oncology (ASCO) guidelines endorse these assays, though some clinical contexts still lack definitive recommendations. The dynamic landscape of EBC management demands further refinement and optimization of genomic assays to streamline their incorporation into clinical practice. The breast cancer community is poised at the brink of transformative advances in enhancing the clinical utility of genomic assays, aiming to significantly improve the precision and effectiveness of both diagnosis and treatment for women with EBC. This article methodically examines the testing methodologies, clinical validity and utility, costs, diagnostic frameworks, and methodologies of the established genomic tests, including the Oncotype Dx Breast Recurrence Score®, MammaPrint, Prosigna®, EndoPredict®, and Breast Cancer Index (BCI). Among these tests, Prosigna and EndoPredict® have at present been validated only on a prognostic level, while Oncotype Dx, MammaPrint, and BCI hold both a prognostic and predictive role. Oncologists and pathologists engaged in the management of EBC will find in this review a thorough comparison of available genomic assays, as well as strategies to optimize the utilization of the information derived from them.

show abstract

Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥70 years with ultralow risk of distant recurrence: A population-based cohort study

Cited by 2 publications

References 4 publications

Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer

Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer

The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy

Contact Info

Product

Resources

About